Apogee Therapeutics $135.11 Per Share AbbVie Sale Under Shareholder Investigation
APGE•Halper Sadeh LLC is investigating Apogee Therapeutics’ $135.11 per share sale to AbbVie for potential breaches of fiduciary duties and restrictive deal terms. The firm may seek increased consideration, additional disclosures or other relief on behalf of Apogee shareholders under a contingent fee structure.
1. Deal Overview
Apogee Therapeutics has agreed to sell its outstanding shares to AbbVie for $135.11 in cash per share, with closing contingent on shareholder and regulatory approvals.
2. Legal Investigation
Halper Sadeh LLC is probing the transaction for potential federal securities law violations and breaches of fiduciary duties, alleging the deal may limit superior competing offers and confer undue benefits on insiders.
3. Potential Shareholder Actions
On behalf of Apogee shareholders, the firm may pursue increased deal consideration, additional disclosures or other relief under a contingent fee arrangement, with no upfront legal costs for investors.
